NOSTRIN and pancreatic ductal adenocarcinoma: Interestingly, NOSTRIN was identified as one of the 36 gene signatures representing prognostic predictor of clinical outcome in pancreatic ductal adenocarcinoma (PDAC), wherein NOSTRIN down-regulation was associated with poor outcome [14].